CHEST Journal | Article

open here please ►
CHEST Journal | Article

Point/Counterpoint Editorials | March 2013

Point: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? Yes

Daniel H. Sterman, MD, FCCP

Author and Funding Information

CHEST. 2013;143(3):597-600. doi:10.1378/chest.12-2546

Text Size: A A A

This editorial/commentary relates to:

• Counterpoint: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? No (CHEST. 2013;143(3):600-602.)


• Rebuttal From Dr Sterman (CHEST. 2013;143(3):602-603.)


• Rebuttal From Dr Lam (CHEST. 2013;143(3):603-604.)

Article

References

Lung cancer is the most common cause of cancer-related death in the United States, with >160,000 new cases per year.^1,2 Over the past several years, there have been remarkable developments in the diagnosis, staging, and treatment of lung cancer, including chest CT scan screening for high-risk individuals with proven survival benefit,³ minimally invasive surgical approaches,⁴ and endobronchial ultrasound (EBUS) as the primary means of mediastinal staging.⁵ All of these innovations combined will have a dramatic impact on the quality and quantity of life in lung cancer victims.